After percutaneous patent foramen ovale (PFO) closure, what platelet inhibition therapy is recommended for a patient already receiving anticoagulation?

Antiplatelet Therapy After PFO Closure in Anticoagulated Patients

In patients already on anticoagulation for other indications who undergo PFO closure, anticoagulation alone is sufficient without adding antiplatelet therapy, as the anticoagulation provides adequate thromboprophylaxis for the device.

Rationale and Evidence-Based Approach

The available guidelines address PFO closure primarily in the context of cryptogenic stroke prevention, where the standard post-closure regimen involves antiplatelet therapy 1. However, your specific clinical scenario—a patient already anticoagulated for another indication—represents a distinct situation not explicitly addressed in the major guidelines.

Standard Post-Closure Antiplatelet Regimen (For Reference)

In patients NOT on anticoagulation, the recommended approach is:

• Dual antiplatelet therapy (DAPT) with aspirin 75 mg/day plus clopidogrel 75 mg/day for 3 months 2
• Followed by single antiplatelet therapy (aspirin or clopidogrel) for ≥5 years 2
• Some evidence suggests DAPT duration may be safely shortened to as little as 3 months or less 3

The Anticoagulated Patient Scenario

Key principle: The primary concern after PFO closure is preventing thrombus formation on the device during the endothelialization period (typically 3-6 months). Anticoagulation provides superior antithrombotic protection compared to antiplatelet therapy.

Clinical Decision Algorithm:

1. If anticoagulation is therapeutic and indicated long-term:

   • Continue anticoagulation alone
   • Do NOT add antiplatelet therapy (increases bleeding risk without proven benefit)
   • The anticoagulation provides adequate device thromboprophylaxis

2. Bleeding risk considerations:

   • The combination of anticoagulation plus antiplatelet therapy significantly increases major bleeding risk 1, 4
   • PFO closure plus antiplatelet therapy alone probably decreases major bleeding compared to anticoagulation 1
   • Adding antiplatelet therapy to existing anticoagulation would create the highest bleeding risk scenario

3. Evidence supporting anticoagulation adequacy:

   • The 2018 BMJ guideline suggests PFO closure plus antiplatelet therapy over anticoagulation therapy alone 1, but this comparison assumes NO device is present
   • Once the device is implanted, anticoagulation provides thromboprophylaxis for both stroke prevention AND device endothelialization
   • No evidence suggests anticoagulation is inadequate for preventing device thrombosis

Important Caveats

Monitor for atrial fibrillation: PFO closure increases the risk of persistent atrial fibrillation (approximately 4.6% vs 0.9% without closure) 5. If your patient develops new AF, this may provide additional justification for continuing anticoagulation.

Device-related complications: Approximately 5.9% of patients experience procedural complications 5, and device-related adverse events occur in about 36 per 1000 patients 1. These are independent of antithrombotic strategy.

Duration of therapy: If anticoagulation is eventually discontinued (e.g., temporary indication resolves), transition to single antiplatelet therapy at that time, as the device should be fully endothelialized by 6 months post-procedure.

Practical Implementation

• Continue current anticoagulation at therapeutic levels (INR 2-3 for warfarin, or standard dosing for DOACs)
• Do not add aspirin or clopidogrel
• Follow-up imaging at 3-6 months to confirm device position and absence of thrombus
• Monitor for new atrial fibrillation with clinical assessment

This approach prioritizes mortality and morbidity reduction by avoiding the substantially increased bleeding risk that would result from combining anticoagulation with antiplatelet therapy, while maintaining adequate antithrombotic protection for both the underlying indication and the PFO closure device.